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Abstract 
Autoantibodies against oxidized low-density lipoprotein (LDL) have been reported to be associated with 
atherosclerosis. However, data are not consistent. 
We compared the titres of autoantibodies to malondialdehyde-modified LDL in three groups, a case group with 
angiographically documented severe coronary stenosis ( > 80% stenosis in at least 1 vessel, n = 47), a hospital control 
group with minor stenosis on the coronary angiography ( < 50% stenosis in all three major vessels, n = 47) and a 
healthy population control group with no history of coronary heart disease (n = 49). Age ranged from 26 to 68 
years. Subjects were frequency-matched for gender distribution and storage time of the blood samples. No relevant 
differences in autoantibody titre between case and control groups were found. The mean autoantibody titres ( f SD.) 
were 1.44 + 1.82, 1.46 _+ 1.40 and 1.62 It: 1.95 for cases, hospital controls and population controls, respectively. 
No correlations were found between autoantibody titre and age, number of cigarettes smoked and LDL or total 
cholesterol. Autoantibody titres were correlated with body mass index (r = 0.2) and high-density lipoprotein (HDL) 
(r = - 0.2). Odds ratios (OR) were calculated by tertiles of autoantibody titres for the hospital control group and 
the population control group, respectively. Age-adjusted OR (95% confidence interval) for medium and high 
compared to low autoantibody titre were 0.76 (0.27-2.14) and 1.09 (0.39-2.95) for the comparison between cases and 
hospital controls and 1.09 (0.39-3.07) and 0.90 (0.32-2.56) for the comparison between cases and population 
controls. Adjustment for gender, body mass index, smoking habits and HDL yielded essentially the same results. 
This study does not support an association between autoantibody titres to oxidized LDL and the extent of 
coronary stenosis. 
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1. Introduction 
Studies implying that oxidative modification of 
low-density lipoprotein (LDL) takes place in vivo 
and may play an important role in atherogenesis 
have accumulated over recent years [l-4]. Oxi- 
dized LDL can activate endothelial cells and in- 
duce endothelial damage, thereby allowing blood 
elements and monocytes to enter the sub-endothe- 
lial space, which is the beginning of the athero- 
genie process. As a consequence of oxidation, the 
uptake of LDL by macrophages is accelerated 
and foam cells are formed. Furthermore, modified 
LDL is immunogenic and has the ability to induce 
the formation of autoantibodies [4,5]. Autoanti- 
bodies against epitopes of oxidized LDL have 
been found in several studies in both human 
[6-151 and rabbit [6,15,16] plasma and atheroscle- 
rotic lesions, however data on the relation be- 
tween autoantibody titres and coronary 
atherosclerosis are not consistent [6- 10,12,13,17- 
19]. Though the LDL-oxidation hypothesis is at- 
tractive in explaining the mechanism of 
development of atherosclerosis, direct evidence 
from human studies is still scarce. 
To investigate the association between autoan- 
tibody titres and atherosclerosis, we studied au- 
toantibody titres of three groups differing in levels 
of coronary artery disease, namely a group of 
patients with angiographically documented severe 
atherosclerosis, a group with angiographically 
documented minor or non-atherosclerosis and a 
population-based group with no history of cardio- 
vascular disease (CVD). 
2. Subjects and methods 
2.1. Study population 
Groups of patients and hospital controls were 
selected from participants in a previous hospital- 
based case-control study on angiographically doc- 
umented CVD and plasma levels of cholesterol 
oxidation products. A group of population con- 
trols consisted of participants in the Dutch Na- 
tional Cardiovascular Disease Risk Factor 
Monitoring Project [20]. The hospital groups con- 
sisted of patients who had undergone a coronary 
angiography for suspected CVD in the period 
1991 and 1992 in Rotterdam. Ineligible were those 
patients: over 68 years of age; with a previous 
bypass surgery; with a myocardial infarction (MI) 
in the 12 months prior to the study period; under 
cardiac care for more then 2.5 years; in whom 
more then 2 months elapsed between angiography 
and case selection; who had diabetes mellitus, 
liver, kidney or thyroid disease, or showed evi- 
dence of alcohol or drug abuse. Of the 387 pa- 
tients eligible for this study, 51 refused to 
participate, 22 could not be contacted or were 
otherwise indisposed and 7 had died. From the 
remaining 307 patients, cases were selected on the 
basis of having more then 80% stenosis in at least 
one of the three major coronary vessels, and 
controls having less then 50% stenosis in all three 
major coronary vessels. This left 159 patients (80 
cases and 79 controls) for the original study. For 
the study reported here, 50 cases and 48 controls 
were randomly selected for determination of 
plasma autoantibodies. 
The population control group is a sample out 
of 36000 participants in the Cardiovascular Dis- 
ease Risk Factor Monitoring Project (1987- 1991) 
[20]. For the original study, a random sample of 
men and women aged 20-59 were selected from 
the civil registry of three cities in the Netherlands. 
The study was performed at the basic health 
service in each city. For the study reported here, 
the following selection criteria were used: domi- 
ciled in Amsterdam, the Netherlands, without use 
of hypercholesterolaemic drugs, not under cardiac 
care, no heart surgery (such as bypass surgery), 
without a myocardial infarction. The 51 persons 
selected were frequency-matched for gender distri- 
bution and storage time of the blood samples to 
subjects of the hospital study. 
2.2. Data collection 
For all three groups, information on medical 
history, use of medication, dietary, smoking and 
drinking habits, occupation and family history of 
CVD was obtained through a questionnaire. Fur- 
ther data on height, weight and blood pressure 
were gathered. The hospital cases and controls 
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were seen within 2 months after angiography. 
Fasting venous blood samples were collected into 
a 10 ml EDTA vacutainer tube and the isolated 
plasma was stored at - 80°C. For the population 
control group, non-fasting venous blood samples 
were collected in 10 ml EDTA vacutainer tubes 
and after centrifugation plasma was stored at 
- 20°C. The mean storage period of blood sam- 
ples was 31 f 3 months (mean f SD.). Storage 
periods for cases and control groups were similar. 
2.3. Measurement of anti-MDA-mod$ed LDL 
autoantibodies 
Autoantibody titres were measured by bi-site 
sandwich ELISA using polystyrene microtitre 
plates (Greiner, number 655001, Alphen a/d Rijn, 
The Netherlands). The microtitre plates were 
coated with MDA-LDL (malondialdehyde- 
modified LDL) as antigen (10 pg/ml, 100 pi/well) 
in phosphate-buffered saline (PBS) for 16 h at 
4°C. Plates were washed 4 times with PBS and the 
residual binding sites were blocked with 1% (“/,) 
casein (Merck) in PBS (200 pi/well) for 2 h at 
room temperature. Plates were washed 4 times 
with PBS, 100 ,~l/well of diluted samples for 
autoantibody determination was added, and the 
plates were incubated for 16 h at 4°C. Five dilu- 
tions, 1:8, 1:16, 1:24, 1:32, 1:64 (‘/,), in blocking 
buffer containing 0.05% (“/,) Tween 20 (Merck) 
were applied. After washing 5 times with PBS 
containing 0.05% (“/,) Tween 20, 100 &well 
goat-anti-human IgG-Fc fragment conjugated to 
horseradish peroxidase (Nordic, Tilburg, The 
Netherlands), diluted 1: 11000 in blocking buffer 
containing 0.1% (“/,) casein and 0.05% (“/,) 
Tween 20, was added and the plates were incu- 
bated for 2 h at 37°C. Plates were washed 4 times 
and the peroxidase-labelled conjugate was visual- 
ized using 3,3’,5,5’-tetramethylbenzidine and 
H20, as substrate mixture [21] (Organon Tech- 
nika BV, Boxtel, The Netherlands). Each microt- 
itre plate contained equal numbers of samples 
from the three study groups. 
Extensively modified MDA-LDL was used and 
prepared essentially as described by Palinski et al. 
[6] by incubating 1 mg/ml LDL (prepared from 
pooled plasma from 5 male and 7 female healthy 
volunteers aged 21-35) in PBS, pH 7.4 for 4 h at 
37°C with 0.1 M MDA, freshly prepared from 
malonaldehyde-bis-dimethylacetal (Kodak East- 
man Co.). After conjugation, MDA-LDL was 
extensively dialysed against PBS and stored in the 
presence of 10% sucrose at - 80°C. As additional 
antigen, native LDL (prepared from the above 
mentioned pool) was used in the assay. This LDL 
was protected from oxidation by addition of 10 
,uM EDTA and 20 ,uM butylated hydroxytoluene 
(Sigma) to PBS and stored in the presence of 10% 
sucrose at - 80°C. 
Each microtitre plate contained a dilution series 
(1:8, 1:16, 1:24, 1:32, 1:64 “/J of the above-men- 
tioned pool plasma in triplicate, which was used 
as a reference standard. From the response of 
these dilution series, a reference line for autoanti- 
body response was constructed. Intra- and inter- 
assay coefficients of variation were 6.0% and 
8.3%, respectively, for the reference curves. The 
autoantibody titre is defined as the ratio between 
the dilution on the reference line belonging to the 
autoantibody response in the sample and the orig- 
inal dilution of the sample and is, in general, the 
mean of the four autoantibody titres obtained at 
dilutions 1:8, 1:16, 1:24 and 1:32 (“/,). In most 
cases, the optical density (OD) at the 1:64 (“/J 
dilution was near the background and deviated 
from the linear curve. This dilution was then 
omitted from the calculation. The slopes of the 
calibration curve constructed with reference stan- 
dard and of the curves of the individual samples 
from the patient group and the control groups 
were not identical. About 15% of the sample 
curves deviated from the reference curve, indicat- 
ing that the values calculated for the human sam- 
ples can only be considered as indicators of 
autoantibody concentrations. This allows com- 
parisons between different samples but cannot be 
considered as an accurate measure of the absolute 
autoantibody mass in each sample. 
Alternatively, data are expressed as the absolute 
value for the ratio of autoantibody binding to 
MDA-LDL/native LDL (both as OD), as applied 
by Salonen et al. [9]. The presented value is the 
mean of the ratios obtained at dilutions 1:8 and 
1:32, as the response to native LDL was only 
measured at these dilutions. Binding to native 
248 L.P.L. van de Vijver et al. /Atherosclerosis 122 (1996) 245-253 
Table 1 
Baseline characteristics (mean + S.D.) 
Age (years) 
Body mass index (kg/m’) 




Plasma triglycerides (mmol/l) 
Systolic pressure (mmHg) 
Diastolic (mmHg) pressure 
% Male 
% Smokers 
Cases (n = 47) 
54.2 f 8.9 
26.2 * 3.3 
6.3 k 0.9 
1.1 + 0.3 
4.4 k 0.8 
6.0 f 1.6 
1.8 + 0.8 
135.0 f 19.4 
84.8 k 10.6 
68.1 
25.5 
Hospital controls (n = 47) 
53.5 + 9.2 
25.4 + 2.8 
5.9 5 1.1 
1.3 * 0.4* 
4.0 * 1.0* 
4.9 * 1.7* 
1.5 + 0.8* 
134.0 + 15.1 
83.4 f 10.9 
68.1 
27.7 
Population controls (n = 49) 
49.6 + 7.8’~‘. 
25.9 + 3.4 
5.6 + l.O* 
1.0 * 0.3’3” 
3.9 + 0.9* 
6.3 f 1.9” 
1.7 + 0.9 
127.0 ) 16.5’,** 
79.3 f 10.3* 
67.3 
38.8 
*significant difference (P < 0.05) with cases 
**significant difference (P < 0.05) with hospital controls 
LDL, considered as a non-specific control, is 
defined as the ratio between the autoantibody 
response in the sample to native LDL (as OD) 
and the autoantibody response in the reference 
standard to native LDL (as OD). 
2.4. Analytical measurements 
HDL-cholesterol and triglycerides were deter- 
mined as described by Sullivan et al. [22] and 
Warnick et al. [23]. Total-cholesterol was deter- 
mined with a spectrum analyser (Abbott Labora- 
tories, USA) with CHOD-PAP reagent (cat. no. 
236691, Boehringer Mannheim). LDL-cholesterol 
was calculated with the Friedewald formula [24]. 
With this formula, triglyceride concentrations 
must not exceed 4.52 mmol/l [25]. Subjects who 
had a triglyceride level above 4.52 were excluded 
from further analysis (3 cases, 1 hospital control 
and 2 population controls). 
2.5. Data analysis 
Data analysis was conducted using the BMDP 
statistical package [26]. Basic characteristics for 
the three groups were compared by Student’s 
t-test for unpaired samples (P < 0.05) and by the 
Mann-Whitney test for non-normal distributions. 
Pearson x2 analysis was applied for class vari- 
ables. By means of the Pearson correlation co- 
efficient, the associations between autoantibody 
titres and continuous variables in the total group 
were quantified. 
To adjust differences between cases and con- 
trols for possible confounders, multiple linear re- 
gression was used. Stratified analysis was 
performed to identify confounders or effect 
modifiers. Odds ratios were calculated to quantify 
the association between autoantibody titre and 
coronary stenosis, the patients were divided into 
tertiles based on autoantibody titres in the hospi- 
tal or population control group. Multiple logistic 
regression adjusted the odds ratio for potential 
confounders. 
3. Results 
In Table 1 the baseline characteristics of the 
three study groups are presented. The population 
control group was slightly, though significantly, 
younger than the two hospital groups. No differ- 
ences were seen for body mass index (BMI). The 
hospital control group had higher HDL (high- 
density lipoprotein) and lower LDL and triglyce- 
rides than the cases. The population controls had 
lower total cholesterol, HDL, LDL and systolic 
and diastolic blood pressure than the cases. After 
adjustment for age and smoking habits, the sig- 
nificant difference in HDL disappeared. 
Autoantibody titres between cases (1.44 + 1.82 
(mean f S.D.)), hospital controls (1.46 + 1.40) 
and population controls (1.62 ‘I 1.95) were not 
significantly different. Fig. 1 shows frequency his- 
tograms of the autoantibody titres of the three 
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autoantibody titres against oxidized LDL 
Fig. 1. Distribution of autoantibody levels against MDA-LDL among cases, hospital controls and population controls 
study groups. At the 1:8 and 1:32 dilutions, the Table 2 presents correlation coefficients for the 
autoantibody response to native LDL was mea- total population between risk factors for CVD 
sured. In 42 out of 143 persons, a response higher and autoantibody titres. Only BMI and HDL 
than 0.2 OD in both dilutions was found. These showed a significant relationship with autoanti- 
higher responses to native LDL were equally dis- bodies. When LDL is being oxidized, a series of 
tributed over the three groups as determined with oxidative products of cholesterol are produced 
frequency calculations. Titres to native LDL [27,28]. We, therefore, also assessed the relation- 
(mean (+ S.D.)) were similar for the three ship between cholesterol oxidation products (total 
groups. The OD assessed at dilution 1:8 were 0.34 oxysterols, 7a-OH cholesterol (the main oxys- 
+ 0.35, 0.37 + 0.36 and 0.32 + 0.35 and at the terol, but also an important intermediate in the 
1:32 dilution 0.23 + 0.31, 0.22 + 0.22 and 0.21 bile acid synthetic pathway) and total oxysterols 
f 0.20 for cases, hospital controls and popula- without 7a-OH cholesterol) and autoantibody 
tion controls, respectively. None of the differences titres in the case and the hospital control group. 
reached significancy. Correlations were - 0.05, - 0.02 and - 0.07 for 
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total oxysterols, 7a-OH cholesterol and total mi- 
nus 7ct-OH cholesterol, respectively. None of 
these correlations reached significance. 
Odds ratios for the risk of CVD and autoanti- 
body titre were calculated with logistic regression 
analyses for tertiles of autoantibody titre for cases 
and hospital controls and for cases and popula- 
tion controls. Results are shown in Table 3a. No 
significant associations were observed for autoan- 
tibody titres and CVD. 
Additionally, we performed the analysis on 
data obtained by using the calculation method 
proposed by Salonen et al. [9], in which autoanti- 
body titres are expressed as the ratio titre (binding 
to MDA-LDL divided by binding to native LDL, 
both as OD). The mean ( f SD.) ratio titres for 
cases, hospital controls and population controls 
were 4.54 + 2.96, 4.26 + 2.72 and 4.90 + 3.06, 
respectively. Comparable to the above mentioned 
approach, no relevant differences among the 
groups were found. 
When assessing the correlation coefficients be- 
tween the ratio titre and risk factors for CVD, 
none of the variables age, number of cigarettes, 
BMI, systolic and diastolic blood pressure, total 
cholesterol, HDL, LDL and triglycerides showed 
a significant association (Table 2). 
Odds ratios calculated for tertiles of the ratio 
titre in the control group are presented in Table 
3b. No significant association was found between 
Table 2 
Correlations for all data between autoantibody titres and risk 
factors for CVD 
Total (n = 143) Autoantibody titre Ratio titre* 
Age -0.01 -0.14 
Number of 0.06 -0.08 
cigarettes/day 
Body mass index 0.20” 0.09 
HDL -0.19” -0.15 
Total cholesterol -0.08 -0.13 
Triglycerides 0.03 0.02 
LDL -0.03 -0.10 
Systolic pressure 0.05 0.04 
Diastolic pressure 0.00 0.02 
*Autoantibody titres were calculated according to the method 
proposed by Salonen et al. [9]. 
l *P < 0.05 
Table 3 
Odds ratios and 95% confidence intervals (CI) for the risk of 
CVD in tertiles of auto antibody titres in the controlgroup, for 






Cases hospital controls 
<0.76 1.0 
0.76-1.17 0.76 (0.27-2.14) 
>1.17 1.09 (0.40-2.95) 
Cases/population controls 
<0.75 1.0 
0.75-1.42 1 .ov (0.39-3.07) 
11.42 0.90 (0.32-2.56) 
(a) Ratio titre” 
Cases/hospital controls 
<2.2 1.0 
2.2-4.9 2.22 (0.75-6.58) 
24.9 2.04 (0.67-6.21) 
Cases/population controls 
<3.0 1.0 
3.0-5.9 0.98 (0.36-2.68) 
25.9 0.71 (0.25-2.06) 
1.0 











*Adjusted for gender, age, smoking habits, HDL, body mass 
index. 
“Autoantibody titres were calculated according to the method 
proposed by Salonen et al. [9]. 
cases and hospital controls and between cases and 
population controls. Adjustment for gender, age, 
smoking habits, HDL and BMI had no impact on 
the results. 
4. Discussion 
In this study, no association between coronary 
heart disease and autoantibody titres was found. 
It is unlikely that the absence of differences in 
autoantibody titres is due to flaws in the study 
design. Blood samples were stored at - 80°C or 
- 20°C degrees. There is no reason to assume 
that differences in storage temperature have 
affected the association, as autoantibody titres in 
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plasma at the different storage temperatures were 
within the same range. Storage time for the three 
groups was comparable. 
As it is conceivable that dietary or life-style 
changes may affect LDL oxidation in vivo [29-321 
and thus may alter autoantibody production, the 
cases and hospital controls were examined within 
2 months after the angiography. Thus, dietary 
and life-style changes as a response to the cardiol- 
ogy report are restricted. 
The two hospital groups were slightly older 
than the population group (mean age of 54 and 50 
for hospital and population groups, respectively). 
This could have introduced bias, but no associa- 
tion between autoantibody titres and age was 
found. Further, the result could have been biased 
by smoking habits, since there were more smokers 
in the population control group. Smoking might 
be related to oxidative stress [33-361 and thus 
could increase oxidation of LDL. Yet, no differ- 
ence in autoantibody titres between smokers and 
non-smokers was found and calculation of corre- 
lations between autoantibody titres and number 
of cigarettes smoked did not produce a relevant 
association. In addition, in a previous report we 
did not observe an effect of smoking on suscepti- 
bility of LDL to oxidation [36]. 
We compared the autoantibody titres of the 
cases to both a hospital and a population control 
group. An objective discrimination between cases 
and hospital controls is possible based on the 
angiographical data, implying as a control group 
a group with documented minor stenosis. How- 
ever, in the control group, 64% were scored as 
having no stenosis, 23% had less than 10% steno- 
sis in the 3 vessels and the mean percentage 
stenosis over the 3 vessels did not exceed 30%. 
The population control group was a selection of 
healthy men and women without self-reported 
history of CVD. However, we cannot rule out the 
possibility of people with unknown, clinically 
non-manifested CVD entering the control group. 
In this study, we defined autoantibody titres in 
two different ways: one related to a reference line 
constructed from the response to a reference 
plasma and the other being the ratio between the 
response to MDA-LDL and that to native LDL. 
The advantage of the first method is the use of 
several dilutions. The autoantibody titres pre- 
sented are generally the mean of the autoantibody 
titres obtained at four dilutions. We believe to 
have thus reduced the approximation error. When 
plotting the OD against the concentration, indi- 
vidual curves do not parallel each other. As 
pointed out by Virella et al. [19], we therefore 
should not use these autoantibody titres as an 
absolute measure, but rather as an indicator of 
autoantibody concentrations. The second method 
for expressing autoantibody titres was calculated 
at the 1:8 and 1:32 dilutions. Both methods were 
significantly correlated (r = 0.34, P < 0.001). As 
both ways of expressing the data generate the 
same result, it is justified to conclude that there is 
no reason to assume that our result can be as- 
cribed to our definition of autoantibody titres. 
The results of our study are consistent with 
reports from several groups, in which no differ- 
ence in levels of antibodies were found [6,17- 191, 
but are inconsistent with others [7,9,10,12-141. In
most studies, elevated levels of autoantibodies 
against epitopes of oxidized LDL are reported 
both in subjects with coronary heart disease and 
in healthy controls. Findings of Maggi et al. [lo], 
Salonen et al. [9], Puurunen et al. [13], as well as 
the results of Virella et al. [18] who described 
higher (though not significantly higher) autoanti- 
body titres in hyperlipidaemic persons and in 
subjects with minor atherosclerosis in comparison 
to persons with known CVD, support the idea 
that antibodies are not an indicator of the severity 
of atherosclerosis, i.e. the extent of thickening of 
the vessel wall, but can be used as an indicator for 
an active atherogenic process. In our study, no 
data on the change in extent of stenosis in recent 
years were available. We, therefore, can not ex- 
clude the possibility that subjects were in a stable 
state of atherogenesis. This may provide an expla- 
nation for the lack of difference in our study. 
Another explanation for not fmding a relation 
with the extent of CVD is pointed out by Virella 
et al. [ 191 who suggest hat different persons may 
have different populations of antibodies with a 
different affinity to antigens. 
We conclude that this study does not support 
an association between autoantibody titres to oxi- 
dized LDL and thickening of the vessel wall. We 
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suggest hat clinical studies focus on assessment of 
the relationship between autoantibody levels and 
development of new lesions, e.g. by measurement 
of intima-media thickening by ultrasound. 
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